Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative cancer treatments. The company leverages its proprietary Phospholipid Drug Conjugate (PDC) delivery platform to specifically target and deliver therapeutic agents to cancer cells, aiming to enhance efficacy and reduce off-target effects. Its pipeline includes iopofosine I 131, a radiotherapeutic designed for targeted delivery of iodine-131, currently being investigated in various clinical trials for diseases such as relapsed or refractory Waldenström's macroglobulinemia, multiple myeloma, and pediatric brain tumors. Cellectar's technology platform holds broad potential for developing next-generation cancer-targeting therapies, including chemotherapeutics and radioisotope conjugates. The company's extensive intellectual property portfolio supports exclusivity around its PDC technology and associated programs. Cellectar Biosciences plays a significant role in advancing precision medicine within oncology by focusing on targeted treatment modalities that address unmet medical needs in cancer care.